Please login to the form below

Not currently logged in
Email:
Password:

HIV

This page shows the latest HIV news and features for those working in and with pharma, biotech and healthcare.

Dovato approval key for Glaxo in HIV treatment

Dovato approval key for Glaxo in HIV treatment

The HIV therapy market is also likely to be affected by the arrival of generic versions of lamivudine. ... Gilead’s GS-6207 is a novel HIV-1 capsid inhibitor is seen as a potential component in a future long-acting therapy.

Latest news

  • Trump budget targets rebates, out-of-pocket costs Trump budget targets rebates, out-of-pocket costs

    Away from drug pricing, the budget includes an increase in funding for HIV programmes, a 12.6% drop in funding for the National Institutes of Health (NIH) which is likely to

  • GSK, J&J say monthly injection keeps HIV controlled GSK, J&J say monthly injection keeps HIV controlled

    three-drug oral regime at suppressing levels of HIV, according to the studies, which involved more than 1, 000 subjects.ealthcare’s. ... In three patients on the injectable (1%) there was a failure to suppress HIV, with four cases on oral therapy.

  • Q&A: Nicola Walsby Q&A: Nicola Walsby

    I had the pleasure of working with Emma and serving as a trustee of this incredible charity that supportS young people living with or affected by HIV.

  • Advair generics and acquisitions to hit GSK in 2019 Advair generics and acquisitions to hit GSK in 2019

    Key milestones expected this year include FDA approval for its HIV combination dolutegravir lamivudine in the first half of the year, as well as the filing for its long-acting HIV

  • Gilead awaits CEO and readouts to revive fortunes Gilead awaits CEO and readouts to revive fortunes

    The company’s new ‘one pill once a day’ HIV treatment Biktarvy has become the best HIV launch of all time in the US. ... Gilead’s new drug is facing competition from GSK’s new arrival in HIV, Juluca.

More from news
Approximately 82 fully matching, plus 494 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 3 fully matching, plus 44 partially matching documents found.

Latest appointments

  • Aelix Therapeutics appoints Dr Thomas Hecht Aelix Therapeutics appoints Dr Thomas Hecht

    its HIV vaccine. ... After decades of work to develop a HIV vaccine, I hope to contribute with my experience in building a strong player that I believe has good chances to be amongst the

  • emotive boosts its client services team emotive boosts its client services team

    Fay Lepley also joins the agency as an account executive and has had experience working in PR and healthcare communications across several therapy areas including cardiovascular, diabetes and HIV.

  • GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet

    GlaxoSmithKline has promoted Deborah Waterhouse to replace ViiV Healthcare's CEO Dominique Limet when he steps down from the HIV-focused firm at the end of March. ... We have delivered scientific innovation, while listening and better understanding the

  • Bionor names executive management team additions Bionor names executive management team additions

    Three new starters including chief operating officer and interim CFO. HIV and deadly virus firm Bionor Pharma has revealed a number of new additions to its executive management team. ... Together, they bring a wealth of experience to advance therapeutic

  • MHP Health strengthens team with four hires MHP Health strengthens team with four hires

    She also volunteers for two HIV charities: one based in London, which supports young people who have family members affected by HIV and one that supports the work of people in

More from appointments
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 34 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics